A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

Asthma Clinical Trial

Official title:

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple-dose Subcutaneous Administration of MEDI-563, a Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00783289
• Other study ID #: MI-CP197
• Status: Completed
• Phase: Phase 2
• Start date: November 14, 2008
• Est. completion date: November 17, 2009

Study information

• Verified date: December 2019
• Source: MedImmune LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.

Description:

This is a Phase 2a, randomized, double-blind, placebo-controlled, dose-escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of multiple subcutaneous doses (25, 100, or 200 milligram [mg]) of benralizumab (MEDI-563) in adult subjects with asthma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: November 17, 2009
• Est. primary completion date: November 17, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Male or female subjects

• Age 18 through 80 years at screening

• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations

• Previously documented diagnosis of asthma of more than or equal to (>=) 1 year duration, based on episodic symptoms of airflow obstruction; post-bronchodilator reversibility of airflow obstruction >=12 percent (%) (at screening or documented within 1 year prior to randomization); or proof of a positive response to a methacholine challenge (documented within 1 year prior to randomization) as represented by a provoking concentration of methacholine to cause a 20% fall in forced expiratory volume in 1 second (FEV1); (PC20) less than (<) 8 milligram per milliliter (mg/mL)

• Weight of >=45 kilogram (kg) but less than or equal to (<=) 135 kg (>=100 pounds [lb] but <=300 lb)

• Able to produce spirometry readings that meet American Thoracic Society (ATS)/European Respiratory Society (ERS) standards

• Screening pre-bronchodilator FEV1 >=60%

• Women of childbearing potential, unless surgically sterile (including tubal ligation) and/or at least 2 years post-menopausal, must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of a condom with spermicide by the sexual partner, or sterile sexual partner) for 14 days prior to the first dose of the investigational product on Study Day 0, and must agree to continue using such precautions through Study Day 161. Cessation of birth control after this point should be discussed with a responsible physician

• Men, unless surgically sterile, must likewise use 2 effective methods of birth control (for example, condom with spermicide) and must agree to continue using such contraceptive precautions through End of Study/Study Day 161

• Ability to complete the study period, including follow-up period until Study Day 161 as required by protocol

Exclusion Criteria:

• Previously received benralizumab (MEDI-563)

• History of allergy or reaction to any component of the investigational product formulation

• History of allergy or reaction to any other marketed or experimental monoclonal antibody therapies, intravenous gammaglobulin (IVIG), or blood products

• Receipt of any investigational drug therapy within 30 days prior to randomization into the study or any biologic(s) within 5 half-lives of the agent prior to randomization into the study

• Treatment with an oral or systemic burst of corticosteroids within 4 weeks prior to randomization into the study

• Use of any chronic systemic immunosuppressive drugs, including oral corticosteroids within 4 weeks prior to randomization into the study

• Current use of any oral or ophthalmic beta-adrenergic antagonist (for example, propranolol), must have been stopped 2 weeks prior to randomization into the study

• Current allergy vaccination (immunotherapy)

• History of anaphylaxis

• Lung disease other than persistent asthma (for example, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease [COPD], tuberculosis [TB])

• Acute illnesses or evidence of significant active infection, such as fever >=38.0 degrees Celsius [C] (>=100.5 degrees Fahrenheit [F]) at screening and up through time of the first dose of the investigational product

• History of ingestion of untreated water in a location known to be infected with parasites, resulting in acute or chronic diarrhea; or an untreated parasitic infection within 1 month of randomization

• Pregnancy (women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of the investigational product)

• Lactating woman

• Infection with human immunodeficiency virus (HIV)-1, HIV-2, or hepatitis A, B, or C virus

• History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >= 1 year prior to randomization into the study

• History of cigarette smoking >=10 pack years

• History of alcohol abuse or drug abuse that required treatment <1 year prior to randomization into the study

• Elective surgery planned during the study period

• Evidence of any systemic disease or any finding upon physical examination, laboratory abnormality, chest x-ray (CXR), or electrocardiogram (ECG) that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study results

• Employees of the clinical study site or any other individuals involved with the conduct of the study, or first degree family members of such individuals (that is, parents, siblings, or children)

Related Conditions & MeSH terms

• Asthma

Intervention

Other:
• Placebo
Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.

Biological:
• Benralizumab 25 mg
Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
• Benralizumab 100 mg
Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
• Benralizumab 200 mg
Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.

Locations

Country	Name	City	State
United States	Research Site	Colorado Springs	Colorado
United States	Research Site	Encinitas	California
United States	Research Site	Los Angeles	California
United States	Allergy Associates Research Center	Portland	Oregon
United States	Research Site	Upland	Pennsylvania
United States	Research Site	Wheaton	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
MedImmune LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.	Day 0 to Day 161
Secondary	Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab		Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Secondary	Maximum Observed Serum Concentration (Cmax) for Benralizumab		Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Secondary	Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab	Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.	Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Secondary	Terminal Phase Elimination Half-Life (t1/2) for Benralizumab	Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.	Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Secondary	Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit		Day 0, 28, 56, 84, 112, and 161

External Links

•   Attachments tab: MI-CP197 Redacted Protocol_22_Jul_2015